Manuel Marti-Antonio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Manuel Marti-Antonio has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Bárbara Cancho
Service of Nephrology, Badajoz University Hospital, 06006 Badajoz, Spain
3 shared publications - Celia Chicharro
Department of Biochemistry, Molecular Biology and Physiology, Universidad de Valladolid, Campus Duques de Soria, 42004 Soria, Spain
3 shared publications - Guillermo Gervasini
Department of Medical and Surgical Therapeutics, Medical School, Universidad de Extremadura
3 shared publications - Jose Manuel Valdivielso
Vascular and Renal Translational Research Group, UDETMA, RICORS2040 del ISCIII, IRBLleida, University of Lleida , Lleida
3 shared publications - Laura González-Rodríguez
Department of Medical and Surgical Therapeutics, Medical School, University of Extremadura, 06006 Badajoz, Spain
3 shared publications - Nicolás Roberto Robles
University of Extremadura
3 shared publications
Latest Publications
- Open Access
- 15 November 2026
- Published by Wiley in British Journal of Pharmacology
Oxidative stress and genetic susceptibility to cross‐reactive and selective NSAID hypersensitivity
Background and Purpose: Nonsteroidal anti‐inflammatory drugs (NSAIDs) are a leading cause of drug hypersensitivity reactions (HRs), but genetic determinants of individual susceptibility remain unclear. Here, we identified genetic variants in redox‐ and immune‐related pathways associated with cross‐reactive NSAID hypersensitivity (CR‐NSAID) and single‐NSAID–induced urticaria/angioedema/anaphylaxis (SNIUAA) and to characterize their functional relevance. Experimental Approach: A multicentre prospective case–control study was conducted in Spanish individuals of European ancestry, including patients with confirmed NSAID hypersensitivity and NSAID‐tolerant individuals. Single nucleotide variants (SNVs) in redox‐ and immune‐related genes were genotyped using a two‐stage discovery and independent replication design. SNVs showing significant associations were functionally evaluated by measuring serum glutathione S‐transferase (GST), superoxide dismutase (SOD) and aldo‐keto reductase (AKR) activities according to genotype. Key Results: GSTM5 rs11101989 and GSTZ1 haplotype (rs1046428, rs7975, rs7972) associated with increased susceptibility to CR‐NSAID. Functional analyses demonstrated that carriers of the GSTM5 rs11101989 CC genotype had significantly reduced total serum GST activity. In SNIUAA, SOD1 variants (rs2070424 and rs2833483) associated with increased susceptibility and reduced serum SOD activity. Additionally, AKR1C3 rs34186955 increased susceptibility, whereas AKR1C3 rs12529 and IL4R rs1805016 associated with decreased susceptibility. Integration of genetic and functional data supported involvement of redox‐related pathways in distinct NSAID hypersensitivity phenotypes and identified GSTM5 and SOD1 variants as candidate genetic susceptibility markers. Conclusions and Implications: Genetic variability in redox‐related and immune‐regulatory pathways contributed to susceptibility to cross‐reactive and selective NSAID hypersensitivity. These findings support further validation of biomarker‐based strategies for personalized risk assessment and safer NSAID prescribing. Further validation in independent populations is required.
- 15 November 2026
- Published by Wiley in British Journal of Pharmacology
Open AccessOxidative stress and genetic susceptibility to cross‐reactive and selective NSAID hypersensitivity
Background and Purpose: Nonsteroidal anti‐inflammatory drugs (NSAIDs) are a leading cause of drug hypersensitivity reactions (HRs), but genetic determinants of individual susceptibility remain unclear. Here, we identified genetic variants in redox‐ and immune‐related pathways associated with cross‐reactive NSAID hypersensitivity (CR‐NSAID) and single‐NSAID–induced urticaria/angioedema/anaphylaxis (SNIUAA) and to characterize their functional relevance. Experimental Approach: A multicentre prospective case–control study was conducted in Spanish individuals of European ancestry, including patients with confirmed NSAID hypersensitivity and NSAID‐tolerant individuals. Single nucleotide variants (SNVs) in redox‐ and immune‐related genes were genotyped using a two‐stage discovery and independent replication design. SNVs showing significant associations were functionally evaluated by measuring serum glutathione S‐transferase (GST), superoxide dismutase (SOD) and aldo‐keto reductase (AKR) activities according to genotype. Key Results: GSTM5 rs11101989 and GSTZ1 haplotype (rs1046428, rs7975, rs7972) associated with increased susceptibility to CR‐NSAID. Functional analyses demonstrated that carriers of the GSTM5 rs11101989 CC genotype had significantly reduced total serum GST activity. In SNIUAA, SOD1 variants (rs2070424 and rs2833483) associated with increased susceptibility and reduced serum SOD activity. Additionally, AKR1C3 rs34186955 increased susceptibility, whereas AKR1C3 rs12529 and IL4R rs1805016 associated with decreased susceptibility. Integration of genetic and functional data supported involvement of redox‐related pathways in distinct NSAID hypersensitivity phenotypes and identified GSTM5 and SOD1 variants as candidate genetic susceptibility markers. Conclusions and Implications: Genetic variability in redox‐related and immune‐regulatory pathways contributed to susceptibility to cross‐reactive and selective NSAID hypersensitivity. These findings support further validation of biomarker‐based strategies for personalized risk assessment and safer NSAID prescribing. Further validation in independent populations is required.
- Open Access
- 17 September 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (18) , 3060
Changes in Frailty Status and Functional Capacity Following a Community-Based Nursing-Led Intervention in Older Women: An Exploratory Uncontrolled Pre–Post Study
Background/Objectives: Frailty is a common geriatric syndrome associated with functional decline, dependency, and adverse health outcomes in older adults. Community-based nursing interventions may help prevent or delay frailty by promoting physical activity, health education, and self-care. This exploratory study aimed to describe pre–post changes in frailty status and functional capacity following a community-based nursing intervention among community-dwelling older women. Methods: An exploratory uncontrolled pre–post study was conducted in Spain. Of 35 community-dwelling, non-institutionalized women aged ≥65 years who underwent baseline assessment, 23 provided complete baseline and post-intervention data and were included in the final pre–post analysis. The intervention consisted of a 16-week nursing programme with weekly group sessions focused on adapted physical exercise, health education, and self-care. Frailty was assessed using the FRAIL Scale. Four available components of the Fried phenotype were examined as secondary frailty-related measures. Functional capacity was evaluated using the Barthel Index and the Lawton and Brody Scale. Results: Among the 23 participants included in the final paired pre–post analysis, the proportion classified as frail according to the FRAIL Scale decreased from 47.8% at baseline to 8.7% at post-intervention assessment, while the proportion classified as robust increased from 17.4% to 30.4%. Nine of the eleven participants classified as frail at baseline moved to a less severe frailty category at follow-up. Frailty status changed significantly across the three FRAIL categories (p < 0.001). Additional analyses showed a decrease in difficulty walking 100 m (43.5% to 8.7%; p = 0.008) and in low physical activity (60.9% to 26.1%; p = 0.021). Functional capacity did not change significantly. Participants reported high levels of satisfaction with the programme. Conclusions: Favourable pre–post changes in FRAIL status and selected frailty-related measures were observed among participants who completed the study, while functional capacity remained stable. Given the exploratory uncontrolled design, small analytical sample, and participant attrition, these findings should not be interpreted as evidence of intervention effectiveness. Larger controlled studies are required to determine whether the observed changes can be attributed to the intervention.
- 17 September 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (18) , 3060
Open AccessChanges in Frailty Status and Functional Capacity Following a Community-Based Nursing-Led Intervention in Older Women: An Exploratory Uncontrolled Pre–Post Study
Background/Objectives: Frailty is a common geriatric syndrome associated with functional decline, dependency, and adverse health outcomes in older adults. Community-based nursing interventions may help prevent or delay frailty by promoting physical activity, health education, and self-care. This exploratory study aimed to describe pre–post changes in frailty status and functional capacity following a community-based nursing intervention among community-dwelling older women. Methods: An exploratory uncontrolled pre–post study was conducted in Spain. Of 35 community-dwelling, non-institutionalized women aged ≥65 years who underwent baseline assessment, 23 provided complete baseline and post-intervention data and were included in the final pre–post analysis. The intervention consisted of a 16-week nursing programme with weekly group sessions focused on adapted physical exercise, health education, and self-care. Frailty was assessed using the FRAIL Scale. Four available components of the Fried phenotype were examined as secondary frailty-related measures. Functional capacity was evaluated using the Barthel Index and the Lawton and Brody Scale. Results: Among the 23 participants included in the final paired pre–post analysis, the proportion classified as frail according to the FRAIL Scale decreased from 47.8% at baseline to 8.7% at post-intervention assessment, while the proportion classified as robust increased from 17.4% to 30.4%. Nine of the eleven participants classified as frail at baseline moved to a less severe frailty category at follow-up. Frailty status changed significantly across the three FRAIL categories (p < 0.001). Additional analyses showed a decrease in difficulty walking 100 m (43.5% to 8.7%; p = 0.008) and in low physical activity (60.9% to 26.1%; p = 0.021). Functional capacity did not change significantly. Participants reported high levels of satisfaction with the programme. Conclusions: Favourable pre–post changes in FRAIL status and selected frailty-related measures were observed among participants who completed the study, while functional capacity remained stable. Given the exploratory uncontrolled design, small analytical sample, and participant attrition, these findings should not be interpreted as evidence of intervention effectiveness. Larger controlled studies are required to determine whether the observed changes can be attributed to the intervention.
- Open Access
- 27 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (3) , 1005
Interplay Between Fibroblast Growth Factor-19, Beta-Klotho, and Receptors Impacts Cardiovascular Risk in Chronic Kidney Disease
Background: Chronic kidney disease (CKD) markedly increases the risk of cardiovascular events (CVE), yet conventional biomarkers often fail to capture this excess risk. We evaluated whether circulating levels and genetic variability within the FGF19/β-Klotho/FGFR axis contribute to CV risk stratification in CKD. Methods: In 579 CKD patients, plasma FGF19 and β-Klotho concentrations were quantified, and 64 genetic variants across FGF19, KLB, FGFR1, and FGFR4 genes were analyzed. Results: Cluster analysis identified three distinct biomarker profiles, with one cluster—characterized by low/intermediate FGF19 and markedly elevated β-Klotho—showing significantly reduced CV event-free survival. After adjustment for clinical covariates, this cluster was independently associated with higher CV risk [HR = 2.97 (1.12–7.92), p = 0.029]. Two genetic variants also showed independent associations: FGFR1 rs2288696 (protective) [HR = 0.51 (0.27–0.95), p = 0.029] and KLB rs2687971 (risk-increasing) [HR = 2.03 (0.97–4.27), p = 0.046]. A combined CV risk model incorporating biomarker clusters, relevant SNPs, and traditional risk factors achieved good discriminative ability (C-index = 0.80), with the FGF19/β-Klotho cluster showing predictive importance comparable to diabetes and previous CV history. Conclusions: These results indicate that integrating FGF19-Klotho biomarkers with genetic information may improve CV risk prediction in CKD.
- 27 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (3) , 1005
Open AccessInterplay Between Fibroblast Growth Factor-19, Beta-Klotho, and Receptors Impacts Cardiovascular Risk in Chronic Kidney Disease
Background: Chronic kidney disease (CKD) markedly increases the risk of cardiovascular events (CVE), yet conventional biomarkers often fail to capture this excess risk. We evaluated whether circulating levels and genetic variability within the FGF19/β-Klotho/FGFR axis contribute to CV risk stratification in CKD. Methods: In 579 CKD patients, plasma FGF19 and β-Klotho concentrations were quantified, and 64 genetic variants across FGF19, KLB, FGFR1, and FGFR4 genes were analyzed. Results: Cluster analysis identified three distinct biomarker profiles, with one cluster—characterized by low/intermediate FGF19 and markedly elevated β-Klotho—showing significantly reduced CV event-free survival. After adjustment for clinical covariates, this cluster was independently associated with higher CV risk [HR = 2.97 (1.12–7.92), p = 0.029]. Two genetic variants also showed independent associations: FGFR1 rs2288696 (protective) [HR = 0.51 (0.27–0.95), p = 0.029] and KLB rs2687971 (risk-increasing) [HR = 2.03 (0.97–4.27), p = 0.046]. A combined CV risk model incorporating biomarker clusters, relevant SNPs, and traditional risk factors achieved good discriminative ability (C-index = 0.80), with the FGF19/β-Klotho cluster showing predictive importance comparable to diabetes and previous CV history. Conclusions: These results indicate that integrating FGF19-Klotho biomarkers with genetic information may improve CV risk prediction in CKD.
- Open Access
- 19 December 2025
- Published by MDPI AG in Preprints.org
Interplay Between Fibroblast Growth Factor-19, Beta-Klotho and Receptors Impact Cardiovascular Risk in Chronic Kidney Disease
Chronic kidney disease (CKD) markedly increases the risk of cardiovascular events (CVE), yet conventional biomarkers often fail to capture this excess risk. We evaluated whether circulating levels and genetic variability within the FGF19/β-Klotho/FGFR axis contribute to CV risk stratification in CKD. In 579 CKD patients, plasma FGF19 and β-Klotho con-centrations were quantified, and 64 genetic variants across FGF19, KLB, FGFR1 and FGFR4 genes were analyzed. Cluster analysis identified three distinct biomarker profiles, with one cluster—characterized by low/intermediate FGF19 and markedly elevated β-Klotho—showing significantly reduced CV event-free survival. After adjustment for clinical covariates, this cluster was independently associated with higher CV risk [HR=2.97 (1.12–7.92), p=0.029]. Two genetic variants also showed independent associa-tions: FGFR1 rs2288696 (protective) [HR=0.51 (0.27–0.95), p=0.029] and KLB rs2687971 (risk-increasing) [HR=2.03 (0.97–4.27), p=0.046]. A combined CV risk model incorporating biomarker clusters, relevant SNPs and traditional risk factors achieved good discrimina-tive ability (C-index = 0.80), with the FGF19/β-Klotho cluster showing predictive im-portance comparable to diabetes and previous CV history. These findings suggest that in-tegrating FGF19-Klotho biomarkers with genetic information may enhance CV risk pre-diction in CKD.
- 19 December 2025
- Published by MDPI AG in Preprints.org
Open AccessInterplay Between Fibroblast Growth Factor-19, Beta-Klotho and Receptors Impact Cardiovascular Risk in Chronic Kidney Disease
Chronic kidney disease (CKD) markedly increases the risk of cardiovascular events (CVE), yet conventional biomarkers often fail to capture this excess risk. We evaluated whether circulating levels and genetic variability within the FGF19/β-Klotho/FGFR axis contribute to CV risk stratification in CKD. In 579 CKD patients, plasma FGF19 and β-Klotho con-centrations were quantified, and 64 genetic variants across FGF19, KLB, FGFR1 and FGFR4 genes were analyzed. Cluster analysis identified three distinct biomarker profiles, with one cluster—characterized by low/intermediate FGF19 and markedly elevated β-Klotho—showing significantly reduced CV event-free survival. After adjustment for clinical covariates, this cluster was independently associated with higher CV risk [HR=2.97 (1.12–7.92), p=0.029]. Two genetic variants also showed independent associa-tions: FGFR1 rs2288696 (protective) [HR=0.51 (0.27–0.95), p=0.029] and KLB rs2687971 (risk-increasing) [HR=2.03 (0.97–4.27), p=0.046]. A combined CV risk model incorporating biomarker clusters, relevant SNPs and traditional risk factors achieved good discrimina-tive ability (C-index = 0.80), with the FGF19/β-Klotho cluster showing predictive im-portance comparable to diabetes and previous CV history. These findings suggest that in-tegrating FGF19-Klotho biomarkers with genetic information may enhance CV risk pre-diction in CKD.
- Open Access
- 10 October 2025
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 144, 106542
Endothelin-1 as dual marker for renal function decline and associated cardiovascular complications in patients with chronic kidney disease
- 10 October 2025
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 144, 106542
Open AccessEndothelin-1 as dual marker for renal function decline and associated cardiovascular complications in patients with chronic kidney disease
- 1 August 2023
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 43 (8) , 1533-1548
Vitamin D Receptor From VSMCs Regulates Vascular Calcification During CKD: A Potential Role for miR-145a
BACKGROUND: Vascular calcification (VC) is a highly prevalent complication of chronic kidney disease (CKD) and is associated with the higher morbidity-mortality of patients with CKD. VDR (vitamin D receptor) has been proposed to play a role in the osteoblastic differentiation of vascular smooth muscle cells (VSMCs), but the involvement of vitamin D in VC associated to CKD is controversial. Our aim was to determine the role of local vitamin D signaling in VSMCs during CKD-induced VC. METHODS: We used epigastric arteries from CKD-affected patients and individuals with normal renal function, alongside an experimental model of CKD-induced VC in mice with conditional deletion of VDR in VSMC. In vitro, experiments in VSMC with or without VDR incubated in calcification media were also used. RESULTS: CKD-affected patients and mice with CKD showed an increase in VC, together with increased arterial expression of VDR compared with controls with normal renal function. Conditional gene silencing of VDR in VSMCs led to a significant decrease of VC in the mouse model of CKD, despite similar levels of renal impairment and serum calcium and phosphate levels. This was accompanied by lower arterial expression of OPN (osteopontin) and lamin A and higher expression of SOST (sclerostin). Furthermore, CKD-affected mice showed a reduction of miR-145a expression in calcified arteries, which was significantly recovered in animals with deletion of VDR in VSMC. In vitro, the absence of VDR prevented VC, inhibited the increase of OPN, and reestablished the expression of miR-145a. Forced expression of miR-145a in vitro in VDR wt VSMCs blunted VC and decreased OPN levels. CONCLUSIONS: Our study provides evidence proving that inhibition of local VDR signaling in VSMCs could prevent VC in CKD and indicates a possible role for miR-145a in this process.
- 1 August 2023
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 43 (8) , 1533-1548
Vitamin D Receptor From VSMCs Regulates Vascular Calcification During CKD: A Potential Role for miR-145a
BACKGROUND: Vascular calcification (VC) is a highly prevalent complication of chronic kidney disease (CKD) and is associated with the higher morbidity-mortality of patients with CKD. VDR (vitamin D receptor) has been proposed to play a role in the osteoblastic differentiation of vascular smooth muscle cells (VSMCs), but the involvement of vitamin D in VC associated to CKD is controversial. Our aim was to determine the role of local vitamin D signaling in VSMCs during CKD-induced VC. METHODS: We used epigastric arteries from CKD-affected patients and individuals with normal renal function, alongside an experimental model of CKD-induced VC in mice with conditional deletion of VDR in VSMC. In vitro, experiments in VSMC with or without VDR incubated in calcification media were also used. RESULTS: CKD-affected patients and mice with CKD showed an increase in VC, together with increased arterial expression of VDR compared with controls with normal renal function. Conditional gene silencing of VDR in VSMCs led to a significant decrease of VC in the mouse model of CKD, despite similar levels of renal impairment and serum calcium and phosphate levels. This was accompanied by lower arterial expression of OPN (osteopontin) and lamin A and higher expression of SOST (sclerostin). Furthermore, CKD-affected mice showed a reduction of miR-145a expression in calcified arteries, which was significantly recovered in animals with deletion of VDR in VSMC. In vitro, the absence of VDR prevented VC, inhibited the increase of OPN, and reestablished the expression of miR-145a. Forced expression of miR-145a in vitro in VDR wt VSMCs blunted VC and decreased OPN levels. CONCLUSIONS: Our study provides evidence proving that inhibition of local VDR signaling in VSMCs could prevent VC in CKD and indicates a possible role for miR-145a in this process.
- Open Access
Natural and Induced Tolerance to Hymenoptera Venom: A Single Mechanism?
Inducing tolerance in Hymenoptera-allergic patients, bee venom immunotherapy (BVIT) is a widely accepted method to treat severe allergy to bee stings. In order to increase the existing knowledge on the underlying immunological mechanisms and look for possible biomarkers predictive of efficacy, a group of 20 bee-venom-allergic patients (AG) were thoroughly examined during their first year of BVIT. In addition, the results of treated patients with those of an untreated group of 20 tolerant beekeepers (TG) who had previously shown a firm suppressor-regulatory profile were compared. Tolerance in AG patients was invariably associated with a significant regulatory response characterised by the expansion of Helios− subpopulation and increased IL-10, specific IgG4 (sIgG4), and kynurenine levels. Although specific IgE (sIgE) levels increased transiently, surprisingly, the T helper type 2 (Th2) population and IL-4 levels rose significantly after one year of immunotherapy. Thus, the picture of two parallel phenomena emerges: a tolerogenic response and an allergenic one. Comparing these results with those obtained from the TG, different immunological mechanisms appear to govern natural and acquired tolerance to immunotherapy. Of particular interest, the kynurenine levels and T regulatory (Treg) Helios− population could be proposed as new biomarkers of response to BVIT.
Open AccessNatural and Induced Tolerance to Hymenoptera Venom: A Single Mechanism?
Inducing tolerance in Hymenoptera-allergic patients, bee venom immunotherapy (BVIT) is a widely accepted method to treat severe allergy to bee stings. In order to increase the existing knowledge on the underlying immunological mechanisms and look for possible biomarkers predictive of efficacy, a group of 20 bee-venom-allergic patients (AG) were thoroughly examined during their first year of BVIT. In addition, the results of treated patients with those of an untreated group of 20 tolerant beekeepers (TG) who had previously shown a firm suppressor-regulatory profile were compared. Tolerance in AG patients was invariably associated with a significant regulatory response characterised by the expansion of Helios− subpopulation and increased IL-10, specific IgG4 (sIgG4), and kynurenine levels. Although specific IgE (sIgE) levels increased transiently, surprisingly, the T helper type 2 (Th2) population and IL-4 levels rose significantly after one year of immunotherapy. Thus, the picture of two parallel phenomena emerges: a tolerogenic response and an allergenic one. Comparing these results with those obtained from the TG, different immunological mechanisms appear to govern natural and acquired tolerance to immunotherapy. Of particular interest, the kynurenine levels and T regulatory (Treg) Helios− population could be proposed as new biomarkers of response to BVIT.
- Open Access
- 29 April 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (5) , 720
Common UGT1A6 Variant Alleles Determine Acetaminophen Pharmacokinetics in Man
Acetaminophen (paracetamol) is a widely used drug that causes adverse drug events that are often dose-dependent and related to plasma drug concentrations. Acetaminophen metabolism strongly depends on UGT1A enzymes. We aimed to investigate putative factors influencing acetaminophen pharmacokinetics. We analyzed acetaminophen pharmacokinetics after intravenous administration in 186 individuals, and we determined the effect of sex; body mass index (BMI); previous and concomitant therapy with UGT1A substrates, inhibitors, and inducers; as well as common variations in the genes coding for UGT1A1, UGT1A6, and UGT1A9. We identified sex and UGT1A6 genetic variants as major factors influencing acetaminophen pharmacokinetics, with women showing lower clearance (p < 0.001) and higher area under the plasma drug concentration-time curve (AUC) values than men (p < 0.001). UGT1A6 genetic variants were related to decreased acetaminophen biodisposition. Individuals who were homozygous or double-heterozygous for variant UGT1A6 alleles showed a 22.5% increase in t1/2 values and a 22.8 increase in drug exposure (p < 0.001, and 0.006, respectively) after correction by sex. The effect is related to the UGT1A6*2 and UGT1A6*4 variant alleles, whereas no effect of UGT1A6*3 and UGT1A9*3 alleles, BMI, or drug–drug interaction was identified in this study. We conclude that sex and UGT1A6 variants determine acetaminophen pharmacokinetics, thus providing evidence to eventually developing pharmacogenomics procedures and recommendations for acetaminophen use.
- 29 April 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (5) , 720
Open AccessCommon UGT1A6 Variant Alleles Determine Acetaminophen Pharmacokinetics in Man
Acetaminophen (paracetamol) is a widely used drug that causes adverse drug events that are often dose-dependent and related to plasma drug concentrations. Acetaminophen metabolism strongly depends on UGT1A enzymes. We aimed to investigate putative factors influencing acetaminophen pharmacokinetics. We analyzed acetaminophen pharmacokinetics after intravenous administration in 186 individuals, and we determined the effect of sex; body mass index (BMI); previous and concomitant therapy with UGT1A substrates, inhibitors, and inducers; as well as common variations in the genes coding for UGT1A1, UGT1A6, and UGT1A9. We identified sex and UGT1A6 genetic variants as major factors influencing acetaminophen pharmacokinetics, with women showing lower clearance (p < 0.001) and higher area under the plasma drug concentration-time curve (AUC) values than men (p < 0.001). UGT1A6 genetic variants were related to decreased acetaminophen biodisposition. Individuals who were homozygous or double-heterozygous for variant UGT1A6 alleles showed a 22.5% increase in t1/2 values and a 22.8 increase in drug exposure (p < 0.001, and 0.006, respectively) after correction by sex. The effect is related to the UGT1A6*2 and UGT1A6*4 variant alleles, whereas no effect of UGT1A6*3 and UGT1A9*3 alleles, BMI, or drug–drug interaction was identified in this study. We conclude that sex and UGT1A6 variants determine acetaminophen pharmacokinetics, thus providing evidence to eventually developing pharmacogenomics procedures and recommendations for acetaminophen use.
- Open Access
Magnesium Levels Modify the Effect of Lipid Parameters on Carotid Intima Media Thickness
Classical risk factors of atherosclerosis in the general population show paradoxical effects in chronic kidney disease (CKD) patients. Thus, low low-density lipoprotein (LDL) cholesterol levels have been associated with worse cardiovascular outcomes. Magnesium (Mg) is a divalent cation whose homeostasis is altered in CKD. Furthermore, Mg levels have been associated with cardiovascular health. The present study aims to understand the relationships of Mg and lipid parameters with atherosclerosis in CKD. In this analysis, 1754 participants from the Observatorio Nacional de Atherosclerosis en Nefrologia (NEFRONA) cohort were included. Carotid intima media thickness (cIMT) was determined in six arterial territories, and associated factors were investigated by linear regression. cIMT correlated positively with being male, Caucasian, a smoker, diabetic, hypertensive, dyslipidemic and with increased age, BMI, and triglyceride levels, and negatively with levels of HDL cholesterol. First-order interactions in linear regression analysis showed that Mg was an effect modifier on the influence of lipidic parameters. Thus, cIMT predicted values were higher when triglycerides or LDL levels were high and Mg levels were low. On the contrary, when Mg levels were high, this effect disappeared. In conclusion, Mg acts as an effect modifier between lipidic parameters and atherosclerotic cardiovascular disease. Therefore, Mg levels, together with lipidic parameters, should be taken into account when assessing atherosclerotic risk.
Open AccessMagnesium Levels Modify the Effect of Lipid Parameters on Carotid Intima Media Thickness
Classical risk factors of atherosclerosis in the general population show paradoxical effects in chronic kidney disease (CKD) patients. Thus, low low-density lipoprotein (LDL) cholesterol levels have been associated with worse cardiovascular outcomes. Magnesium (Mg) is a divalent cation whose homeostasis is altered in CKD. Furthermore, Mg levels have been associated with cardiovascular health. The present study aims to understand the relationships of Mg and lipid parameters with atherosclerosis in CKD. In this analysis, 1754 participants from the Observatorio Nacional de Atherosclerosis en Nefrologia (NEFRONA) cohort were included. Carotid intima media thickness (cIMT) was determined in six arterial territories, and associated factors were investigated by linear regression. cIMT correlated positively with being male, Caucasian, a smoker, diabetic, hypertensive, dyslipidemic and with increased age, BMI, and triglyceride levels, and negatively with levels of HDL cholesterol. First-order interactions in linear regression analysis showed that Mg was an effect modifier on the influence of lipidic parameters. Thus, cIMT predicted values were higher when triglycerides or LDL levels were high and Mg levels were low. On the contrary, when Mg levels were high, this effect disappeared. In conclusion, Mg acts as an effect modifier between lipidic parameters and atherosclerotic cardiovascular disease. Therefore, Mg levels, together with lipidic parameters, should be taken into account when assessing atherosclerotic risk.